T. Rowe Price Health Sciences Fund (PRHSX)

81.12
Net Asset Value
+1.26%
1 Day
+19.31%
Year-to-Date
Overall Morningstar Rating
Health
Style or Category
No Load
Sales Expenses
0.77%
Expense Ratio
Above Average
Morningstar Risk Rating™
Investment Objective The investment seeks long-term capital appreciation. The fund will normally invest at least 80% of its net assets (including any borrowings for investment purposes) in the common stocks of companies engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences (collectively termed "health sciences"). While the fund can invest in companies of any size, the majority of fund assets are expected to be invested in large- and mid-capitalization companies.

Performance

1 month+0.68% 3 years+38.31%
3 months+5.60% 5 years+32.92%
1 year+47.45% Since inception+15.88%
Data through --

Peer Comparisonvs. Health

 PRHSXCategory
Performance 5-yr return+32.92%+22.35%
Expense ratio0.77%1.42%
Risk 5 year sharpe ratio1.741.48
Net assets$14.1B$3.7B
Average market cap$21.4B$35.4B
Average P/E27.524.6
Portfolio turnover42%42%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyT. Rowe Price
Fund manager & tenureTaymour Tamaddon / 2 Years
Minimal initial investment$2,500.00
Minimum IRA investment$1,000.00

Holdings

U.S. stock77.43%
International stock15.64%
Cash5.78%
Fixed income0.78%
Other0.38%
Top 5 Sectors
Portfolio weighting
Healthcare 93.76%
Industrial materials 0.91%
Consumer service 0.89%
Financial service 0.38%
Telecommunication 0.19%
Top 10 Holdings
Portfolio weighting
ACT Actavis5.33%
-- 3.76%
GILD Gilead Sciences3.60%
-- 3.53%
ALXN Alexion Pharmaceuticals Inc3.41%
MCK McKesson Corp3.21%
AET Aetna3.10%
UNH UnitedHealth2.91%
BIIB Biogen2.36%
HUM Humana Inc2.33%

To view my watchlist

Not a member yet?

Sign up now for a free account